Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Cost-effectiveness of newborn screening for cystic fibrosis determined with real-life data.

Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society - 1 Mar 2015

van der Ploeg C P B, van den Akker-van Marle M E, Vernooij-van Langen A M M, Elvers L H, Gille J J P, Verkerk P H, Dankert-Roelse J E

Abstract excerpt

BACKGROUND: Previous cost-effectiveness studies using data from the literature showed that newborn screening for cystic fibrosis (NBSCF) is a good economic option with positive health effects and longer survival. METHODS: We used primary data to compare cost-effectiveness of four screening strategies for NBSCF, i.e. immunoreactive trypsinogen-testing followed by pancreatitis-associated protein-testing (IRT-PAP),...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antigens, Neoplasm
Share to Cost-Benefit Analysis

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Decision Support Techniques

Share to Lectins, C-Type

Share to Neonatal Screening

Share to Netherlands

Share to Pancreatitis-Associated Proteins

Share to Trypsinogen

Source

Identifiers

PMID: 25213034
DOI: 10.1016/j.jcf.2014.08.007

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Cost-effectiveness of newborn screening for cystic fibrosis determined with real-life data.PMID 25213034Read ↗

Newborn blood spot screening for cystic fibrosis with a four-step screening strategy in the Netherlands.Semantic proximity Read ↗

Novel strategies in newborn screening for cystic fibrosis: a prospective controlled study.Semantic proximity Read ↗

Four-year evaluation of neonatal cystic fibrosis screening in Southern Belgium.Semantic proximity Read ↗

Initial evaluation of a biochemical cystic fibrosis newborn screening by sequential analysis of immunoreactive trypsinogen and pancreatitis-associated protein (IRT/PAP) as a strategy that does not involve DNA testing in a Northern European population.Semantic proximity Read ↗

Bayesian cost-effectiveness analysis of Whole genome sequencing versus Whole exome sequencing in a pediatric population with suspected genetic disordersSemantic proximity Read ↗

Cost-effectiveness of pancreatic cancer screening in familial pancreatic cancer kindreds.Semantic proximity Read ↗

Carrier Screening for Cystic FibrosisSemantic proximity Read ↗

Genetic screening by DNA technology: a systematic review of health economic evidence.Semantic proximity Read ↗

Newborn Cystic Fibrosis Diagnosis Made Accurate and Efficient with Machine Learning to Reduce False Positives in IRT-Trypsinogen Immunoreactive Screening ProgramSemantic proximity Read ↗

Cost-Benefit Analysis of Genetic Testing as a Prenatal Diagnostic Tool for Thalassemia: A Single-Center Study From Central ThailandSemantic proximity Read ↗

Estimating Direct Cost of Cystic Fibrosis Care Using Irish Registry Healthcare Resource Utilisation Data, 2008-2012.Semantic proximity Read ↗

Lessons learned from 20 years of newborn screening for cystic fibrosis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.